An audit of high dose-rate prostate brachytherapy treatment planning at six Swedish clinics

CONCLUSIONS: Dose constraints for the organs at risk are showing a larger variation than that reflected in compared treatments plans. In all treatment plans in our audit, at least 10 Gy was administered giving a total treatment of 102 Gy EQD2, which is in the upper part of the prescription doses published in the GEC/ESTRO recommendations.PMID:34025738 | PMC:PMC8117718 | DOI:10.5114/jcb.2021.103588
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research